| [1] |
冯力.雷替曲塞联合奥沙利铂治疗晚期结直肠癌临床效果观察 [J]. 临床误诊误治, 2012, 25(2): 43-46.
|
| [2] |
EUSTACE K. Colorectal cancer [J]. Lancel, 2005, 365(9454): 166.
|
| [3] |
Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history [J]. Cancer, 2013, 49(10): 2303-2310.
|
| [4] |
Avallone A, Di Gennaro E, Silvestro L, et al. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed [J]. Expert Opin Drug Saf, 2014, 13(1): 113-129.
|
| [5] |
Abstracts of the 37th ESMO(European Society for Medical Oncology) Congress. September 28-October 2, 2012 Vienna, Austria [J]. Ann Oncol, 2012, 23(Suppl 9): ixl78-ix223.
|
| [6] |
Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited [J]. Expert Opin Drug Saf, 2009, 8(2): 191-202.
|
| [7] |
Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice [J]. Anticancer Res, 2014, 34(4): 1531-1535.
|
| [8] |
L Lemaire, MC Malet-Martino, M de Forni, et al.Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug [J]. British Journal of Cancer, 1992, 66: 119-127.
|
| [9] |
Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature [J]. J Clin Oncol, 2012, 30(2): e11-e14.
|
| [10] |
Lieutaud T, Brain E, Golgran-Toledano D, et al. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure [J]. Eur J Cancer, 1996, 32(2): 368-369.
|
| [11] |
Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm [J]. Am Heart J, 1987, 114(2): 443-436.
|
| [12] |
Kuropkat C, Griem K, Clark J, et al. Severe cardiotoxicity during 5-flurorouracil chemotherapy: A case and literature support [J]. Am J Clin 0ncol, 1999, 22(5): 466-470.
|
| [13] |
Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer [J]. Cancer, 2006, 72(7): 2242-2248.
|
| [14] |
Cunningham D, Zalcberg JR, Rath U, et al. FIinal results of a randomized trial comparing ′Tomudex′(raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. ″Tomudex″ Colorectal Cancer Study Group [J]. Ann Oncol, 1996, 7(9): 961-965.
|
| [15] |
Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus highdose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group [J]. J Clin Oncol, 1998, 16(9): 2943-2452.
|
| [16] |
Cunningham D. Mature results from three large controlled studies with raltitrexed (′Tomudex′) [J]. Br J Cancer, 1998, 77(supp12): 15-21.
|
| [17] |
Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: anaudit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines [J]. Ann Oncol, 2014, 25(1): 117-121.
|
| [18] |
Wilson KS, Fitzgerald CA, Barnett JB, et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience [J]. Cancer Invest, 2007, 25(8): 711-714.
|